Skip to main content

Antidepressant discontinuation during pregnancy and relapse risk in the perinatal period

Project description

Towards personalised anti-depressant therapy in pregnancy

Up to 10 % of women take antidepressant medication during pregnancy. However, half of them stop treatment in fear of the potential impact on the embryo. Treatment discontinuation increases the risk of relapse with profound consequences. Since evidence so far relies purely on epidemiological data, in order to determine the risk factors, the EU-funded PregnancyAD project will integrate demographics, clinical features and genetic data from a large representative population in Denmark. Addressing the genetics knowledge gap in the field will help identify women at high risk of relapse after discontinuing antidepressants during pregnancy. More importantly, it will contribute towards optimal antidepressant treatment recommendations during pregnancy.

Coordinator

AARHUS UNIVERSITET
Net EU contribution
€ 201 392,64
Address
Nordre Ringgade 1
8000 Aarhus C
Denmark

See on map

Region
Danmark Midtjylland Østjylland
Activity type
Higher or Secondary Education Establishments
Non-EU contribution
€ 0,00

Partners (1)

Partner

Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.

THE UNIVERSITY OF QUEENSLAND
Australia
Net EU contribution
€ 0,00
Non-EU contribution
€ 91 736,64